StockData

InflaRx vs Kiora Pharmaceuticals

IFRX and KPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IFRX and KPRX compare

Kiora Pharmaceuticals scores higher on the StockData Score (7 against 5 for InflaRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIFRXKPRX
Size and price
Market cap–$4.1M
Share price$1.15$0.930
Change, 1 year−14.8%−56.9%
Change, 5 years−77.4%−99.8%
Beta (5Y)3.711.65
Employees–3,500
StockData Score
Total score57 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/B–0.2×
FCF yield–−209%
Growth
Revenue growth (TTM)−82.3%–
Profitability
Gross margin−24678%–
Return on equity–−56.4%
Return on invested capital–−1374%
Financial health
Debt / equity0.000.00
Current ratio4.138.97 (better)
Altman Z-score–−9.82
Piotroski F-score–3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions135%25.0%
Held by insiders6.0%3.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.